Cargando…
Risk Factors for and Effects of Persistent and Severe Hypophosphatemia Following Ferric Carboxymaltose
CONTEXT: Hypophosphatemia, osteomalacia, and fractures are complications of certain intravenous iron formulations. OBJECTIVE: This study investigated risk factors for incident, severe, and persistent hypophosphatemia, and associated alterations in bone and mineral biomarkers following intravenous ir...
Autores principales: | , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8947794/ https://www.ncbi.nlm.nih.gov/pubmed/34850000 http://dx.doi.org/10.1210/clinem/dgab852 |
_version_ | 1784674522605027328 |
---|---|
author | Schaefer, Benedikt Zoller, Heinz Wolf, Myles |
author_facet | Schaefer, Benedikt Zoller, Heinz Wolf, Myles |
author_sort | Schaefer, Benedikt |
collection | PubMed |
description | CONTEXT: Hypophosphatemia, osteomalacia, and fractures are complications of certain intravenous iron formulations. OBJECTIVE: This study investigated risk factors for incident, severe, and persistent hypophosphatemia, and associated alterations in bone and mineral biomarkers following intravenous iron treatment. METHODS: We analyzed data from the PHOSPHARE-IDA randomized clinical trials, comprising 245 patients aged 18 years or older with iron deficiency anemia at 30 outpatient clinics in the United States who received intravenous ferric carboxymaltose (FCM) or ferric derisomaltose (FDI). Outcome measures included serum phosphate, intact fibroblast growth factor-23 (iFGF23), 1,25-dihydroxyvitamin D (1,25(OH)(2)D), ionized calcium, parathyroid hormone (PTH), and alkaline phosphatase. RESULTS: FCM was the only consistent risk factor for incident hypophosphatemia (< 2.0 mg/dL; odds ratio vs FDI: 38.37; 95% CI: 16.62, 88.56; P < 0.001). Only FCM-treated patients developed severe hypophosphatemia (< 1.0 mg/dL; 11.3%; 13/115) or persistent hypophosphatemia (< 2.0 mg/dL at study end; 40.0%; 46/115). More severe hypophosphatemia associated with significantly greater increases in iFGF23, PTH, and alkaline phosphatase, and more severe decreases in 1,25(OH)(2)D and ionized calcium (all P < 0.05). Patients with persistent vs resolved hypophosphatemia demonstrated significantly greater changes in iFGF23, PTH, 1,25(OH)(2)D, and N-terminal procollagen-1 peptide levels (all P < 0.01), but alkaline phosphatase increased similarly in both groups. CONCLUSION: Treatment with FCM was the only consistent risk factor for hypophosphatemia. Patients who developed severe or persistent hypophosphatemia after FCM treatment manifested more severe derangements in bone and mineral metabolism. Changes in bone biomarkers continued beyond resolution of hypophosphatemia, suggesting ongoing effects on bone that may help explain the association of FCM with osteomalacia and fractures. |
format | Online Article Text |
id | pubmed-8947794 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Oxford University Press |
record_format | MEDLINE/PubMed |
spelling | pubmed-89477942022-03-28 Risk Factors for and Effects of Persistent and Severe Hypophosphatemia Following Ferric Carboxymaltose Schaefer, Benedikt Zoller, Heinz Wolf, Myles J Clin Endocrinol Metab Clinical Research Article CONTEXT: Hypophosphatemia, osteomalacia, and fractures are complications of certain intravenous iron formulations. OBJECTIVE: This study investigated risk factors for incident, severe, and persistent hypophosphatemia, and associated alterations in bone and mineral biomarkers following intravenous iron treatment. METHODS: We analyzed data from the PHOSPHARE-IDA randomized clinical trials, comprising 245 patients aged 18 years or older with iron deficiency anemia at 30 outpatient clinics in the United States who received intravenous ferric carboxymaltose (FCM) or ferric derisomaltose (FDI). Outcome measures included serum phosphate, intact fibroblast growth factor-23 (iFGF23), 1,25-dihydroxyvitamin D (1,25(OH)(2)D), ionized calcium, parathyroid hormone (PTH), and alkaline phosphatase. RESULTS: FCM was the only consistent risk factor for incident hypophosphatemia (< 2.0 mg/dL; odds ratio vs FDI: 38.37; 95% CI: 16.62, 88.56; P < 0.001). Only FCM-treated patients developed severe hypophosphatemia (< 1.0 mg/dL; 11.3%; 13/115) or persistent hypophosphatemia (< 2.0 mg/dL at study end; 40.0%; 46/115). More severe hypophosphatemia associated with significantly greater increases in iFGF23, PTH, and alkaline phosphatase, and more severe decreases in 1,25(OH)(2)D and ionized calcium (all P < 0.05). Patients with persistent vs resolved hypophosphatemia demonstrated significantly greater changes in iFGF23, PTH, 1,25(OH)(2)D, and N-terminal procollagen-1 peptide levels (all P < 0.01), but alkaline phosphatase increased similarly in both groups. CONCLUSION: Treatment with FCM was the only consistent risk factor for hypophosphatemia. Patients who developed severe or persistent hypophosphatemia after FCM treatment manifested more severe derangements in bone and mineral metabolism. Changes in bone biomarkers continued beyond resolution of hypophosphatemia, suggesting ongoing effects on bone that may help explain the association of FCM with osteomalacia and fractures. Oxford University Press 2021-11-25 /pmc/articles/PMC8947794/ /pubmed/34850000 http://dx.doi.org/10.1210/clinem/dgab852 Text en © The Author(s) 2021. Published by Oxford University Press on behalf of the Endocrine Society. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs licence (https://creativecommons.org/licenses/by-nc-nd/4.0/), which permits non-commercial reproduction and distribution of the work, in any medium, provided the original work is not altered or transformed in any way, and that the work is properly cited. For commercial re-use, please contact journals.permissions@oup.com |
spellingShingle | Clinical Research Article Schaefer, Benedikt Zoller, Heinz Wolf, Myles Risk Factors for and Effects of Persistent and Severe Hypophosphatemia Following Ferric Carboxymaltose |
title | Risk Factors for and Effects of Persistent and Severe Hypophosphatemia Following Ferric Carboxymaltose |
title_full | Risk Factors for and Effects of Persistent and Severe Hypophosphatemia Following Ferric Carboxymaltose |
title_fullStr | Risk Factors for and Effects of Persistent and Severe Hypophosphatemia Following Ferric Carboxymaltose |
title_full_unstemmed | Risk Factors for and Effects of Persistent and Severe Hypophosphatemia Following Ferric Carboxymaltose |
title_short | Risk Factors for and Effects of Persistent and Severe Hypophosphatemia Following Ferric Carboxymaltose |
title_sort | risk factors for and effects of persistent and severe hypophosphatemia following ferric carboxymaltose |
topic | Clinical Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8947794/ https://www.ncbi.nlm.nih.gov/pubmed/34850000 http://dx.doi.org/10.1210/clinem/dgab852 |
work_keys_str_mv | AT schaeferbenedikt riskfactorsforandeffectsofpersistentandseverehypophosphatemiafollowingferriccarboxymaltose AT zollerheinz riskfactorsforandeffectsofpersistentandseverehypophosphatemiafollowingferriccarboxymaltose AT wolfmyles riskfactorsforandeffectsofpersistentandseverehypophosphatemiafollowingferriccarboxymaltose |